Patents by Inventor Robert Seder
Robert Seder has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240117026Abstract: Antibodies and antigen binding fragments that specifically bind to P. falciparum circumsporozoite protein and neutralize P. falciparum are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. The disclosed antibodies, antigen binding fragments, nucleic acids and vectors can be used, for example, to inhibit a P. falciparum infection.Type: ApplicationFiled: August 2, 2023Publication date: April 11, 2024Applicants: The U.S.A., as Represented by the Secretary, Department of Health and Human Services, Sanaria Inc.Inventors: Robert Seder, Neville Kisalu, Azza Idris, Barbara Flynn, Stephen Hoffman
-
Patent number: 11938177Abstract: Embodiments of a novel platform for delivering a peptide antigen to a subject to induce an immune response to the peptide antigen are provided. For example, nanoparticle polyplexes are provided that comprise a polymer linked to a peptide conjugate by an electrostatic interaction. The conjugate comprises a peptide antigen linked to a peptide tag through an optional linker. An adjuvant may be included in the nanoparticle polyplex, linked to either the polymer or the conjugate, or admixed with the nanoparticles. The nanoparticle polyplex can be administered to a subject to induce an immune response to the peptide antigen.Type: GrantFiled: November 2, 2021Date of Patent: March 26, 2024Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Robert Seder, Geoffrey Lynn
-
Patent number: 11865168Abstract: Provided herein are compositions and methods for therapeutic and/or prophylactic treatment of an intracellular bacterial infection in a subject in need thereof, comprising one or more modulating agents, wherein the one or more modulating agents increase expression of IFN?, IL-2, TNF, and/or IL-17 in systemic and/or lung T cells. In some embodiments, the increase of expression of IFN?, IL-2, TNF, and/or IL-17 occurs in lung T cells. The lung T cells can be lung resident T cells or systemic T cells that are recruited to the lung. In some embodiments, the T cells are CD4+ and/or CD8+ T cells. In some embodiments, the intracellular bacterial infection is a Mycobacterium tuberculosis (MTB) infection.Type: GrantFiled: December 30, 2020Date of Patent: January 9, 2024Assignees: Massachusetts Institute of Technology, The United States of America, as represented by The Secretary, Department of Health & Human Services, University of Pittsburgh—Of The Commonwealth System of Higher EducationInventors: Alexander K. Shalek, Travis Hughes, Marc H. Wadsworth, Robert Seder, Mario Roederer, Joanne L. Flynn, Patricia Darrah
-
Patent number: 11760794Abstract: Antibodies and antigen binding fragments that specifically bind to P. falciparum circumsporozoite protein and neutralize P. falciparum are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. The disclosed antibodies, antigen binding fragments, nucleic acids and vectors can be used, for example, to inhibit a P. falciparum infection.Type: GrantFiled: April 28, 2021Date of Patent: September 19, 2023Assignees: The United States of America, as Represented by the Secretary, Department of Health and Human Services, Sanaria Inc.Inventors: Robert Seder, Neville Kisalu, Azza Idris, Barbara Flynn, Stephen Hoffman
-
Publication number: 20220227853Abstract: Antibodies and antigen binding fragments that specifically bind to P. falciparum circumsporozoite protein are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. The disclosed antibodies, antigen binding fragments, nucleic acids and vectors can be used, for example, to inhibit a P. falciparum infection.Type: ApplicationFiled: May 4, 2020Publication date: July 21, 2022Applicant: The United States of America,as represented by the Secretary,Department of Health and Human ServicesInventors: Robert Seder, Lawrence Wang, Rachel Vistein, Joseph Francica
-
Publication number: 20220152170Abstract: Embodiments of a novel platform for delivering a peptide antigen to a subject to induce an immune response to the peptide antigen are provided. For example, nanoparticle polyplexes are provided that comprise a polymer linked to a peptide conjugate by an electrostatic interaction. The conjugate comprises a peptide antigen linked to a peptide tag through an optional linker. An adjuvant may be included in the nanoparticle polyplex, linked to either the polymer or the conjugate, or admixed with the nanoparticles. The nanoparticle polyplex can be administered to a subject to induce an immune response to the peptide antigen.Type: ApplicationFiled: November 2, 2021Publication date: May 19, 2022Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServicInventors: Robert Seder, Geoffrey Lynn
-
Patent number: 11191821Abstract: Embodiments of a novel platform for delivering a peptide antigen to a subject to induce an immune response to the peptide antigen are provided. For example, nanoparticle polyplexes are provided that comprise a polymer linked to a peptide conjugate by an electrostatic interaction. The conjugate comprises a peptide antigen linked to a peptide tag through an optional linker. An adjuvant may be included in the nanoparticle polyplex, linked to either the polymer or the conjugate, or admixed with the nanoparticles. The nanoparticle polyplex can be administered to a subject to induce an immune response to the peptide antigen.Type: GrantFiled: February 27, 2017Date of Patent: December 7, 2021Assignee: The United States of America as represented by the Secretary, Department of Health and Human ServicesInventors: Robert Seder, Geoffrey Lynn
-
Publication number: 20210253683Abstract: Antibodies and antigen binding fragments that specifically bind to P. falciparum circumsporozoite protein and neutralize P. falciparum are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. The disclosed antibodies, antigen binding fragments, nucleic acids and vectors can be used, for example, to inhibit a P. falciparum infection.Type: ApplicationFiled: April 28, 2021Publication date: August 19, 2021Applicants: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVIC, Sanaria Inc.Inventors: Robert Seder, Neville Kisalu, Azza Idris, Barbara Flynn, Stephen Hoffman
-
Publication number: 20210213126Abstract: Provided herein are compositions and methods for therapeutic and/or prophylactic treatment of an intracellular bacterial infection in a subject in need thereof, comprising one or more modulating agents, wherein the one or more modulating agents increase expression of IFN?, IL-2, TNF, and/or IL-17 in systemic and/or lung T cells. In some embodiments, the increase of expression of IFN?, IL-2, TNF, and/or IL-17 occurs in lung T cells. The lung T cells can be lung resident T cells or systemic T cells that are recruited to the lung. In some embodiments, the T cells are CD4+ and/or CD8+ T cells. In some embodiments, the intracellular bacterial infection is a Mycobacterium tuberculosis (MTB) infection.Type: ApplicationFiled: December 30, 2020Publication date: July 15, 2021Inventors: Alexander K. Shalek, Travis Hughes, Marc H. Wadsworth, Robert Seder, Mario Roederer, Joanne L. Flynn, Patricia Darrah
-
Patent number: 11021535Abstract: Antibodies and antigen binding fragments that specifically bind to P. falciparum circumsporozoite protein and neutralize P. falciparum are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. The disclosed antibodies, antigen binding fragments, nucleic acids and vectors can be used, for example, to inhibit a P. falciparum infection.Type: GrantFiled: February 12, 2018Date of Patent: June 1, 2021Assignees: The United States of America as represented by the Secretary, Department of Health and Human Services, Sanaria Inc.Inventors: Robert Seder, Neville Kisalu, Azza Idris, Barbara Flynn, Stephen Hoffman
-
Publication number: 20210023208Abstract: Embodiments of a novel system for delivering an expression vector encoding an antigen to a subject that allows for spatiotemporal control over stimulation of the subject's immune response to the antigen are provided. In some embodiments, the expression vector delivery system includes a polymer linked to an adjuvant in prodrug form that can form polymer nanoparticles and enter a cell (such as an immune cell) under physiological conditions. In some embodiments, the adjuvant is linked to the polymer by an enzyme degradable labile bond, the cleavage of which activates the adjuvant to stimulate an immune response.Type: ApplicationFiled: October 6, 2020Publication date: January 28, 2021Applicants: The United States of America, as represented by the Secretary, Department of Health and Human Servic, The Chancellor, Masters and Scholars of the University of OxfordInventors: Robert Seder, Geoffrey Lynn, Leonard Seymour
-
Publication number: 20210000934Abstract: The invention relates to an adjuvant comprising Pattern Recognition Receptor (PRR) agonist molecules linked to polymer chains that are capable of undergoing particle formation in aqueous conditions, or in aqueous conditions in response to external stimuli; and methods of treatment or prevention of disease using such an adjuvant.Type: ApplicationFiled: June 22, 2020Publication date: January 7, 2021Applicants: Oxford University Innovation Limited, The U.S.A., as Represented by the Secretary, Department of Health and Human ServicesInventors: Kerry Fisher, Richard Laga, Geoffrey Lynn, Leonard Seymour, Robert Seder
-
Patent number: 10799580Abstract: Embodiments of a novel system for delivering an expression vector encoding an antigen to a subject that allows for spatiotemporal control over stimulation of the subject's immune response to the antigen are provided. In some embodiments, the expression vector delivery system includes a polymer linked to an adjuvant in prodrug form that can form polymer nanoparticles and enter a cell (such as an immune cell) under physiological conditions. In some embodiments, the adjuvant is linked to the polymer by an enzyme degradable labile bond, the cleavage of which activates the adjuvant to stimulate an immune response.Type: GrantFiled: September 9, 2016Date of Patent: October 13, 2020Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, The Chancellor, Masters and Scholars of the University of OxfordInventors: Robert Seder, Geoffrey Lynn, Leonard Seymour
-
Publication number: 20190375831Abstract: Antibodies and antigen binding fragments that specifically bind to P. falciparum circumsporozoite protein and neutralize P. falciparum are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. The disclosed antibodies, antigen binding fragments, nucleic acids and vectors can be used, for example, to inhibit a P. falciparum infection.Type: ApplicationFiled: February 12, 2018Publication date: December 12, 2019Applicants: HUMAN SERVICES, SANARIA INCInventors: Robert Seder, Neville Kisalu, Azza Idris, Barbara Flynn, Stephen Hoffman
-
Publication number: 20190060435Abstract: Embodiments of a novel platform for delivering a peptide antigen to a subject to induce an immune response to the peptide antigen are provided. For example, nanoparticle polyplexes are provided that comprise a polymer linked to a peptide conjugate by an electrostatic interaction. The conjugate comprises a peptide antigen linked to a peptide tag through an optional linker. An adjuvant may be included in the nanoparticle polyplex, linked to either the polymer or the conjugate, or admixed with the nanoparticles. The nanoparticle polyplex can be administered to a subject to induce an immune response to the peptide antigen.Type: ApplicationFiled: February 27, 2017Publication date: February 28, 2019Applicant: The United States of America, as represented by the Secretary, Dept of Health and Human ServiceInventors: Robert Seder, Geoffrey Lynn
-
Patent number: 10197577Abstract: Disclosed herein are diagnostic methods and compositions for identifying individuals that are protected against Plasmodium falciparum caused malaria. Such methods are particularly useful for determining not only the protective efficacy of Pf whole parasite vaccines for individual subjects, but also within populations of vaccinated subjects. Also disclosed herein are subunit vaccines comprising at least one Pf immunologic determinant for protection against Plasmodium-caused malaria.Type: GrantFiled: December 29, 2017Date of Patent: February 5, 2019Assignees: Sanaria Inc., Antigen Discovery, Inc., The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Philip Felgner, Stephen L. Hoffman, Robert Seder, Joseph J. Campo, Jr.
-
Publication number: 20180280497Abstract: Embodiments of a novel system for delivering an expression vector encoding an antigen to a subject that allows for spatiotemporal control over stimulation of the subject's immune response to the antigen are provided. In some embodiments, the expression vector delivery system includes a polymer linked to an adjuvant in prodrug form that can form polymer nanoparticles and enter a cell (such as an immune cell) under physiological conditions. In some embodiments, the adjuvant is linked to the polymer by an enzyme degradable labile bond, the cleavage of which activates the adjuvant to stimulate an immune response.Type: ApplicationFiled: September 9, 2016Publication date: October 4, 2018Applicants: The Chancellor, Masters and Scholars of the University of OxfordInventors: Robert SEDER, Geoffrey LYNN, Leonard SEYMOUR
-
Publication number: 20180231566Abstract: Disclosed herein are diagnostic methods and compositions for identifying individuals that are protected against Plasmodium falciparum caused malaria. Such methods are particularly useful for determining not only the protective efficacy of Pf whole parasite vaccines for individual subjects, but also within populations of vaccinated subjects. Also disclosed herein are subunit vaccines comprising at least one Pf immunologic determinant for protection against Plasmodium-caused malaria.Type: ApplicationFiled: December 29, 2017Publication date: August 16, 2018Applicants: Sanaria Inc., Antigen Discovery, Inc., The United States of America, as represented by the Secretary, Department of Health and HumanInventors: Philip FELGNER, Stephen L. HOFFMAN, Robert SEDER, Joseph J. CAMPO, JR.
-
Publication number: 20170304420Abstract: The invention relates to an adjuvant comprising Pattern Recognition Receptor (PRR) agonist molecules linked to polymer chains that are capable of undergoing particle formation in aqueous conditions, or in aqueous conditions in response to external stimuli; and methods of treatment or prevention of disease using such an adjuvant.Type: ApplicationFiled: October 9, 2015Publication date: October 26, 2017Applicants: Oxford University Innovation Limited, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVInventors: Kerry Fisher, Richard Laga, Geoffrey Lynn, Leonard Seymour, Robert Seder
-
Publication number: 20160320404Abstract: Disclosed herein are diagnostic methods and compositions for identifying individuals that are protected against Plasmodium falciparum caused malaria. Such methods are particularly useful for determining not only the protective efficacy of Pf whole parasite vaccines for individual subjects, but also within populations of vaccinated subjects. Also disclosed herein are subunit vaccines comprising at least one Pf immunologic determinant for protection against Plasmodium-caused malaria.Type: ApplicationFiled: March 4, 2016Publication date: November 3, 2016Applicants: Sanaria Inc., Antigen Discovery, Inc., The United States of America, as represented by the Secretary, Department of Health and HumanInventors: Philip FELGNER, Stephen L. HOFFMAN, Robert SEDER, Joseph J. CAMPO, Jr.